Trial Profile
Phase III study of tumour-infiltrating lymphocytes [Contego] in combination with check point inhibitors/T-cells for metastatic melanoma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2013
Price :
$35
*
At a glance
- Drugs Lifileucel (Primary) ; Cell therapies; Checkpoint kinase inhibitors
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 08 Nov 2013 New trial record